跳至主要内容
临床试验/NCT06489600
NCT06489600已完成不适用

Open-Label, Interventional, Prospective, Safety, In-Use Tolerability Study of Test Product "No Rays, Thanks Mineral Sunscreen" in Healthy Adult Subjects With Dry and Sensitive Skin.

NovoBliss Research Pvt Ltd2 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2024年12月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
27
试验地点
2
主要终点
Change in local intolerance assessment for skin irritation using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

研究概览

简要总结

This is open-label, interventional, prospective, safety in-use tolerability study of test product "No Rays, Thanks Mineral Sunscreen" in healthy adult human subjects with dry and sensitive skin.

详细描述

A total of 27 subjects with preferably equal number of males and non-pregnant /non-lactating females will be enrolled to ensure a total of 25 subjects complete the study.

The potential subjects will be screened as per the inclusion & exclusion criteria only after obtaining written informed consent from the subjects. Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be called on the telephone by the recruiting department prior to the enrolment visit. Subjects will be told during screening (prior to enrolment) not to wear any facial make-up on the study visit day. The adult male and female subjects will be instructed to visit the facility as per the below visits.

  • Visit 01 (Day 01): Screening, Enrolment, Baseline Evaluation, on site product usage, Post usage evaluation at T15 mins.
  • Visit 02 (Day 15 ±2 Days): Evaluations, End of Study

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18 to 55 years (both inclusive) at the time of consent.
  • Sex: Healthy male and non-pregnant/non-lactating females. (Preferably equal ratio of males and females)
  • Females of childbearing potential must have a self-reported negative pregnancy test.
  • Subject are generally in good health.
  • Subject with dry and sensitive skins. (As per the dermatological evaluation).
  • Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
  • If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
  • Subjects are willing to give written informed consent and are willing to come for regular follow up.
  • Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study.
  • Subject who have not participated in a similar investigation in the past three months.
  • Willing to use test product throughout the study period.

排除标准

  • History of any dermatological condition of the skin disease.
  • Subject with present condition of allergic response to any cosmetic product.
  • Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.
  • History of alcohol or drug addiction.
  • The subject has clinically significant skin disease, which may contraindicate participation, including psoriasis, eczema, skin cancer or other skin pathology.
  • Subjects having skin infections like bacterial, fungal, viral infections.
  • The subject has skin irritation, open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the face that can interfere with the reading.
  • Be wearing any facial makeup, including false eyelashes, on the day of the study visit.
  • Subjects having hypersensitive skin.
  • Subjects using other marketed sun screen products during the study period.
  • Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion.
  • Pregnant or breastfeeding or planning to become pregnant during the study period.
  • History of chronic illness which may influence the cutaneous state.
  • Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.

结局指标

主要结局

Change in local intolerance assessment for skin irritation using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

时间窗: On Day 01 at T15 minutes and on Day 15 (± 2 Days).

To assess the safety of the test product in terms of change in local intolerance assessment for irritation by dermatological assessment

Change in local intolerance assessment for skin dryness using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

时间窗: On Day 01 at T15 minutes and on Day 15 (± 2 Days).

To assess the safety of the test product in terms of change in local intolerance assessment for dryness by dermatological assessment

Change in local intolerance assessment for skin oedema using 4-point scoring scale where 0 indicate absent and 3 indicate severe.

时间窗: On Day 01 at T15 minutes and on Day 15 (± 2 Days).

To assess the safety of the test product in terms of change in local intolerance assessment for oedema by dermatological assessment

safety of the test product in terms of local intolerance assessment of irritation (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.

时间窗: On Day 01 at T15 minutes and on Day 15 (± 2 Days).

To evaluate the safety of the test product in terms of local intolerance assessment of irritation by Patient Global Assessment scale.

safety of the test product in terms of local intolerance assessment of dryness (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.

时间窗: On Day 01 at T15 minutes and on Day 15 (± 2 Days).

To evaluate the safety of the test product in terms of local intolerance assessment of dryness by Patient Global Assessment scale.

safety of the test product in terms of local intolerance assessment of oedema (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.

时间窗: On Day 01 at T15 minutes and on Day 15 (± 2 Days).

To evaluate the safety of the test product in terms of local intolerance assessment of oedema by Patient Global Assessment scale.

次要结局

  • where will you rank the test product in terms of appearance in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of spreadibility in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of texture in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of fragrance in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of absorption in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of colour in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of tackiness in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of non-sticky/non-oily in which 1 indicate very poor and 5 indicate excellent.(On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of light weight in which 1 indicate very poor and 5 indicate excellent.(On Day 01 after usage of test product at T15 minutes, and on Day 15 (±2 Days))
  • where will you rank the test product in terms of satisfaction in which 1 indicate very poor and 5 indicate excellent.(On Day 01 after usage of test product at T15 minutes, and on Day 15 (±2 Days))

研究者

发起方
NovoBliss Research Pvt Ltd
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
1 期
ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot UlcersDiabetesNon-healing WoundDiabetic Foot Ulcer
NCT02657876Stratatech, a Mallinckrodt Company5
已完成
不适用
An open label study to assess the safety and tolerability of PB006 administered as a single intravenous infusioMultiple Sclerosis
NL-OMON48246bioeq GmbH10
招募中
1 期
Phase I study of a Latanoprost Ocular Implant for treatment of Open Angle Glaucoma or Ocular Hypertension.Ocular Hypertension
ACTRN12621001718831PolyActiva Pty Ltd6
进行中(未招募)
1 期
Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia SyndromeFamilial Chylomicronemia SyndromeMedDRA version: 20.0Level: PTClassification code 10058108Term: DyslipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2018-002911-80-ITPRM|2121820
进行中(未招募)
不适用
A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients.oonan syndrome hypertrophic cardiomyopathyMedDRA version: 14.1Level: PTClassification code 10029748Term: Noonan syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10007541 - Cardiac disorders
EUCTR2011-003392-10-GBovartis Pharma Services AG22
A Clinical Study to Assess the Safety, In-use... | 临床试验